New radioactive therapy shows promise for hard-to-treat thyroid cancer
NCT ID NCT02088645
First seen May 04, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-phase study tests a radioactive drug (177Lu-PP-F11N) that targets a receptor found on most medullary thyroid cancer cells. The goal is to see if it can safely image and treat advanced cancers that have spread. About 24 adults with medullary thyroid cancer or certain other neuroendocrine tumors will take part. The study first checks how well the drug finds tumors, then finds the safest dose for treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR GEP GRADE 1-3 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Basel, Clinic for radiology and nuclear medicine
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.